Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting tumor cells.

Pantea Houshmand1, Albert Zlotnik

  • 1Neurocrine Biosciences, 10555 Science Center Drive, San Diego, CA 92121, USA.

Current Opinion in Cell Biology
|October 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leukocyte surface expression of the endoplasmic reticulum chaperone GRP78 is increased in severe COVID-19.

Journal of leukocyte biology·2023
Same author

Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment.

British journal of cancer·2021
Same author

Corrigendum: CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome.

Frontiers in immunology·2021
Same author

Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1).

Frontiers in immunology·2021
Same author

CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome.

Frontiers in immunology·2021
Same author

EGFR/Ras-induced CCL20 production modulates the tumour microenvironment.

British journal of cancer·2020

Targeted cancer therapies using monoclonal antibodies are advancing rapidly. These "magic bullet" approaches identify specific tumor antigens, offering new treatment opportunities and challenges in oncology.

Area of Science:

  • Oncology
  • Immunology
  • Drug Development

Background:

  • The 'magic bullet' concept involves targeting specific antigens on tumor cells.
  • Monoclonal antibodies have emerged as a key therapeutic strategy in cancer treatment.
  • Advances in science and technology enable the development of targeted therapies.

Purpose of the Study:

  • To review the current status and future prospects of monoclonal antibodies in cancer therapy.
  • To discuss the opportunities and challenges associated with targeted cancer therapeutics.
  • To highlight the progression of antibody-based treatments from concept to clinical application.

Main Methods:

  • Review of recent scientific and technical developments in cancer therapeutics.
  • Analysis of the clinical progress of monoclonal antibodies in oncology.

Related Experiment Videos

  • Discussion of the 'magic bullet' concept in relation to targeted antigen identification.

    • Main Results:

    • Monoclonal antibody therapy for cancer has progressed beyond the proof-of-concept stage.
    • Numerous antibody-based therapeutics are currently undergoing clinical trials.
    • Several antibodies are successfully utilized in treating various cancers.

    Conclusions:

    • Monoclonal antibodies represent a significant advancement in cancer treatment.
    • The development of targeted antibody therapies presents both opportunities and challenges.
    • Continued innovation is expected to yield more antibody-based cancer treatments in the near future.